Researchers from the Key Laboratory of Neuropharmacology and Translational Medicine of Zhejiang Province have gained new insights into the role of histamine receptors in fear memories.
Researchers from Alzecure Pharma AB presented preclinical data for ACD-137, a negative allosteric modulator (NAM) of tropomyosin receptor kinase A (TrkA), being developed for the treatment of pain.
Researchers from Contineum Therapeutics Inc. have presented preclinical data for the novel brain penetrant lysophosphatidic acid receptor 1 (LPAR1) antagonist, PIPE-791, being evaluated in models of neuropathic pain.
The interaction between the transcriptional co-repressor runt-related transcription factor 1 translocation partner 1 (Runx1t1) and MYCN, a member of the MYC proto-oncogene family, plays a crucial role in the development of neuroblastoma, according to a study led by the Children's Cancer Institute at Lowy Cancer Centre, UNSW Sydney.
China’s National Medical Products Administration has cleared Luye Pharma Group Ltd.’s new schizophrenia candidate LY-03020 to enter phase I trials in China. Independently developed by Shanghai-based Luye, the new chemical entity is a dual agonist that targets both the trace amine-associated receptor 1 and the 5-HT2C receptor and is intended to treat schizophrenia and Alzheimer’s disease psychosis.
Researchers from Indiana University have presented data from a study that aimed to assess the potential of suppressing GABA metabolism through inhibition of its degradation enzyme, GABA aminotransferase (GABA-AT), as novel analgesic strategy. The effect of next-generation GABA-AT inhibitor OV-329 was assessed in C57BL/6J mice that were intraperitoneally injected with paclitaxel to generate neuropathic nociception. Treatment with OV-329 attenuated the development and maintenance of paclitaxel-induced mechanical hypersensitivity.
Infection or cure? Scientists from Tel Aviv University and the University of Glasgow genetically modified the Toxoplasma gondii to bring a protein inside neurons. The novelty of using a protozoan that can travel from the gut to parasitize the CNS contrasts with the possibility of causing a disease. The scientists are already working on how to avoid it.
Seoul, South Korea-based Adel Inc. raised ₩17 billion (US$12.39 million) in bridge financing to advance its pipeline of Alzheimer’s disease therapies, including its tau antibody-based ADEL-Y01 candidate, currently in a U.S.-based phase I study.
Sangamo Therapeutics Inc. put pen to paper on a would-be $1.9 billion-plus deal with Genentech, a unit of Roche AG, to develop intravenously administered genomic drugs for neurodegenerative conditions.
Big pharma continues to invest heavily into molecular glue degraders. The latest deal has Eisai Co. Ltd. striking up a research collaboration that could bring Seed Therapeutics Inc. up to $1.5 billion in up-front and milestone payments. The two said they plan to discover, develop and commercialize MGDs for several undisclosed neurodegeneration and oncology targets.
RSS
